Cas:123770-62-7 Ethyl 5-(Hydroxymethyl)Isoxazole-3-Carboxylate manufacturer & supplier

We serve Chemical Name:Ethyl 5-(Hydroxymethyl)Isoxazole-3-Carboxylate CAS:123770-62-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Ethyl 5-(Hydroxymethyl)Isoxazole-3-Carboxylate

Chemical Name:Ethyl 5-(Hydroxymethyl)Isoxazole-3-Carboxylate
CAS.NO:123770-62-7
Synonyms:5-Hydroxymethylisoxazole-3-carboxylic acid ethyl ester;3-carbethoxy-5-hydroxymethylisoxazole;3-ethoxycarbonyl-5-hydroxymethylisoxazole
Molecular Formula:C7H9NO4
Molecular Weight:171.15100
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:72.56000
Exact Mass:171.05300
LogP:0.34360

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-Hydroxymethylisoxazole-3-carboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-ethoxycarbonyl-5-hydroxymethylisoxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-ethoxycarbonyl-5-hydroxymethylisoxazole Use and application,3-carbethoxy-5-hydroxymethylisoxazole technical grade,usp/ep/jp grade.


Related News: The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. 2-bromo-6-methoxy-3,4-dihydro-2H-naphthalen-1-one manufacturers Wavelength’s growth in the API space comes as nations around the world look to develop redundant supply chains for key generic medicines amid the pandemic. 4-(furan-2-yl)butan-2-amine suppliers In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. 1-hydroxy-3-oxo-5,6,7,8-tetrahydro-2H-isoquinoline-4-carbonitrile vendor & factory.